Brokerages Set AdaptHealth Corp. (NASDAQ:AHCO) Target Price at $12.10

Shares of AdaptHealth Corp. (NASDAQ:AHCO) have been given a consensus rating of “Hold” by the seven research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $12.10.

A number of research firms have weighed in on AHCO. UBS Group upped their price objective on shares of AdaptHealth from $9.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Jefferies Financial Group downgraded shares of AdaptHealth from a “buy” rating to a “hold” rating and reduced their price target for the stock from $14.50 to $8.00 in a research report on Monday, January 8th. Truist Financial boosted their price objective on AdaptHealth from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $13.00 target price on shares of AdaptHealth in a research report on Monday, March 4th.

AdaptHealth Price Performance

Shares of AdaptHealth stock opened at $10.06 on Monday. The firm has a market cap of $1.34 billion, a PE ratio of -1.89, a P/E/G ratio of 0.66 and a beta of 1.02. AdaptHealth has a twelve month low of $6.37 and a twelve month high of $15.37. The company has a quick ratio of 1.00, a current ratio of 1.21 and a debt-to-equity ratio of 1.44. The business has a 50-day moving average price of $10.21 and a 200 day moving average price of $8.49.

AdaptHealth (NASDAQ:AHCO) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a positive return on equity of 8.84% and a negative net margin of 21.21%. The business had revenue of $858.23 million during the quarter, compared to analysts’ expectations of $825.94 million. Sell-side analysts predict that AdaptHealth will post 0.88 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder James E. Flynn sold 182,607 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $11.02, for a total value of $2,012,329.14. Following the completion of the sale, the insider now directly owns 11,643,769 shares in the company, valued at $128,314,334.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other AdaptHealth news, major shareholder James E. Flynn sold 52,487 shares of AdaptHealth stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $10.93, for a total transaction of $573,682.91. Following the transaction, the insider now directly owns 11,826,376 shares of the company’s stock, valued at $129,262,289.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder James E. Flynn sold 182,607 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the completion of the transaction, the insider now owns 11,643,769 shares in the company, valued at $128,314,334.38. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AHCO. GAMMA Investing LLC raised its position in AdaptHealth by 197.1% in the first quarter. GAMMA Investing LLC now owns 2,537 shares of the company’s stock valued at $29,000 after purchasing an additional 1,683 shares during the period. Oak Thistle LLC purchased a new stake in AdaptHealth in the 3rd quarter valued at about $94,000. Campbell & CO Investment Adviser LLC acquired a new position in AdaptHealth in the third quarter valued at about $100,000. Raymond James & Associates purchased a new position in AdaptHealth during the third quarter worth about $101,000. Finally, Everence Capital Management Inc. acquired a new stake in shares of AdaptHealth during the fourth quarter valued at about $102,000. 82.67% of the stock is currently owned by institutional investors and hedge funds.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.